SERUM MIR-181А AND MIR-25 LEVELS IN PATIENTS WITH BREAST CANCEROR A BENIGN BREAST DISEASE

A. I. Autenshlyus; Аутеншлюс А. И.; M. L. Perepechaeva; Перепечаева М. Л.; А. А. Studenikina; Студеникина А. А.; А. Y. Grishanova; Гришанова А. Ю.; V. V. Lyakhovich; Ляхович В. В.

doi:10.31857/S2686738923600279

SERUM MIR-181А AND MIR-25 LEVELS IN PATIENTS WITH BREAST CANCEROR A BENIGN BREAST DISEASE

Autores: Autenshlyus A.I.¹^,2, Perepechaeva M.L.¹^,2, Studenikina А.А.¹^,2, Grishanova А.Y.², Lyakhovich V.V.²
Afiliações:
1. Novosibirsk State Medical University
2. Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine
Edição: Volume 512, Nº 1 (2023)
Páginas: 460-465
Seção: Articles
URL: https://journals.rcsi.science/2686-7389/article/view/140854
DOI: https://doi.org/10.31857/S2686738923600279
EDN: https://elibrary.ru/OYHGRJ
ID: 140854

Citar

Texto integral

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

Circulating miR-181а and miR-25, which reflect regulation of the expression of carcinogenesis-related genes, were assayed in patients with invasive carcinoma of no specific type (ICNT) or benign diseases of the breast (BDBs) and in people without pathologies of the mammary gland (controls). MiR-181а expression level proved to be higher compared to control in patients with fibroadenoma and adenosis with low but not high risk of malignant transformation as well as in patients with luminal HER2-negative type B (Lum B HER2–), HER2-positive type (HER2+) and triple-negative breast cancer (TNBC) than in the controls and luminal-type (Lum A) breast cancer. MiR-25 expression level prevailed in patients with Lum B HER2- compared to control, Lum A and TNBC; in patients with TNBC compared to Lum A. Thus, MiR-181а and miR-25 expression levels may be risk indicators of malignant transformation in some patients with BDBs, whereas in patients with ICNT, these levels reflect pathological processes of different directions within the tumor.

Palavras-chave

miR-181а, miR-25, biomarkers, breast cancer, benign breast disease

Bibliografia

Zhai Z., Mu T., Zhao L., Li Y., et al. MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway // Bioengineered. 2022. V. 13. № 1. P. 83–95.
Yang C., Tabatabaei S.N., Ruan X., et al. The Dual Regulatory Role of MiR-181a in Breast Cancer // Cell Physiol Biochem. 2017. V. 44. № 3. P. 843–856.
Mahmoudian M., Razmara E., Mahmud Hussen B., et al. Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues // J Clin Lab Anal. 2021. V. 35. № 11. P. e24010.
Bisso A., Faleschini M., Zampa F., et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer // Cell Cycle. 2013. V. 12. № 11. P. 1679–1687.
Li Y., Kuscu C., Banach A., et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14 // Cancer Res. 2015. V. 75. № 13. P. 2674–2685.
Farazi T.A., Ten Hoeve J.J., Brown M., et al. Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets // Genome Biol. 2014. V. 15. № 1. P. R9.
Wang L.J., Chiou J.T., Lee Y.C., et al. Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF-alpha-mediated apoptosis of cancer cells // Biochem Pharmacol. 2022. V. 195. P. 114865.
Chen H., Pan H., Qian Y., et al. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2 // Mol Cancer. 2018. V. 17. № 1. P. 4.
Yao J., Li G., Liu M., et al. lncMICAL21 sponges miR25 to regulate DKK3 expression and inhibits activation of the Wnt/betacatenin signaling pathway in breast cancer // Int J Mol Med. 2022. V. 49. № 2.
Hu Z.B., Dong J., Wang L.E., et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls // Carcinogenesis. 2012. V. 33. № 4. P. 828–834.
Malherbe K., Khan M., Fatima S. Fibrocystic Breast Disease. Treasure Island (FL):StatPearls Publishing; 2022.
WHO Classification of Tumours Editorial Board, editors.Breast tumours.5nd ed. Lyon: International Agency for Besearch on Cancer; 2019.
Erber R., Angeloni M., Stohr R., et al. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting // Int J Mol Sci. 2022. V. 23. № 15.
Zendehdel M., Niakan B., Keshtkar A., et al. Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol // Iran J Med Sci. 2018. V. 43. № 1. P. 1–8.
Holm K., Hegardt C., Staaf J., et al. Ringner M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns // Breast Cancer Res. 2010. V. 12. № 3. P. R36.
Humphries B., Wang Z., Yang C. MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer // Cancers (Basel). 2019. V. 11. № 7.
Stagni V., Manni I., Oropallo V., et al. ATM kinase sustains HER2 tumorigenicity in breast cancer // Nat Commun. 2015. V. 6. P. 6886.
Taylor M.A., Sossey-Alaoui K., Thompson C.L., et al. TGF-beta upregulates miR-181a expression to promote breast cancer metastasis // Journal of Clinical Investigation. 2013. V. 123. № 1. P. 150–163.
Vishnubalaji R., Alajez N.M. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-beta signaling // Sci Rep. 2021. V. 11. № 1. P. 15410.
Tanic M., Yanowski K., Gomez-Lopez G., et al. MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors // Int J Cancer. 2015. V. 136. № 3. P. 593–602.